Cyclacel Pharmaceuticals (CYCC) Competitors $0.36 -0.01 (-4.01%) (As of 10:31 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CYCC vs. SXTC, LIPO, PBM, INM, ARAV, PCSA, MYMD, ALBT, GNPX, and MTNBShould you be buying Cyclacel Pharmaceuticals stock or one of its competitors? The main competitors of Cyclacel Pharmaceuticals include China SXT Pharmaceuticals (SXTC), Lipella Pharmaceuticals (LIPO), Psyence Biomedical (PBM), InMed Pharmaceuticals (INM), Aravive (ARAV), Processa Pharmaceuticals (PCSA), MyMD Pharmaceuticals (MYMD), Avalon GloboCare (ALBT), Genprex (GNPX), and Matinas Biopharma (MTNB). These companies are all part of the "pharmaceutical products" industry. Cyclacel Pharmaceuticals vs. China SXT Pharmaceuticals Lipella Pharmaceuticals Psyence Biomedical InMed Pharmaceuticals Aravive Processa Pharmaceuticals MyMD Pharmaceuticals Avalon GloboCare Genprex Matinas Biopharma China SXT Pharmaceuticals (NASDAQ:SXTC) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability, community ranking and analyst recommendations. Which has stronger earnings and valuation, SXTC or CYCC? China SXT Pharmaceuticals has higher revenue and earnings than Cyclacel Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChina SXT Pharmaceuticals$1.93M0.78-$3.10MN/AN/ACyclacel Pharmaceuticals$420K1.82-$22.56M-$9.40-0.04 Do analysts rate SXTC or CYCC? Cyclacel Pharmaceuticals has a consensus target price of $11.00, indicating a potential upside of 2,986.42%. Given Cyclacel Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Cyclacel Pharmaceuticals is more favorable than China SXT Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cyclacel Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is SXTC or CYCC more profitable? China SXT Pharmaceuticals has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -18,150.00%. China SXT Pharmaceuticals' return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets China SXT PharmaceuticalsN/A N/A N/A Cyclacel Pharmaceuticals -18,150.00%-1,901.11%-188.23% Does the media refer more to SXTC or CYCC? In the previous week, Cyclacel Pharmaceuticals had 10 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 10 mentions for Cyclacel Pharmaceuticals and 0 mentions for China SXT Pharmaceuticals. Cyclacel Pharmaceuticals' average media sentiment score of 0.67 beat China SXT Pharmaceuticals' score of 0.00 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment China SXT Pharmaceuticals Neutral Cyclacel Pharmaceuticals Positive Does the MarketBeat Community favor SXTC or CYCC? Cyclacel Pharmaceuticals received 105 more outperform votes than China SXT Pharmaceuticals when rated by MarketBeat users. However, 61.65% of users gave China SXT Pharmaceuticals an outperform vote while only 47.34% of users gave Cyclacel Pharmaceuticals an outperform vote. CompanyUnderperformOutperformChina SXT PharmaceuticalsOutperform Votes8261.65% Underperform Votes5138.35% Cyclacel PharmaceuticalsOutperform Votes18747.34% Underperform Votes20852.66% Do insiders and institutionals hold more shares of SXTC or CYCC? 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Comparatively, 8.0% of Cyclacel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, SXTC or CYCC? China SXT Pharmaceuticals has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. SummaryCyclacel Pharmaceuticals beats China SXT Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCC vs. The Competition Export to ExcelMetricCyclacel PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$766,000.00$6.48B$5.07B$8.80BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-0.044.9789.5613.60Price / Sales1.82371.451,224.8087.40Price / CashN/A52.5939.4536.27Price / Book-0.7910.306.976.33Net Income-$22.56M$153.61M$119.04M$225.93M7 Day Performance-9.38%-1.73%-1.78%-0.96%1 Month Performance-73.00%-7.26%-3.59%1.06%1 Year Performance-91.23%31.10%31.64%26.59% Cyclacel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCCCyclacel Pharmaceuticals2.1409 of 5 stars$0.36-4.0%$11.00+2,986.4%-91.7%$766,000.00$420,000.00-0.0414SXTCChina SXT PharmaceuticalsN/A$0.37-2.9%N/A-80.0%$1.51M$1.93M0.0090LIPOLipella Pharmaceuticals2.9825 of 5 stars$2.51+4.1%$16.00+537.5%-74.3%$3.04M$450,000.00-0.604News CoveragePBMPsyence BiomedicalN/A$0.05-6.0%N/AN/A$2.98MN/A0.00N/ANews CoverageGap DownINMInMed Pharmaceuticals0.2095 of 5 stars$4.13-2.4%N/A-47.8%$2.97M$4.60M0.0013ARAVAravive0.8247 of 5 stars$0.04flatN/AN/A$2.95M$9.14M-0.0420High Trading VolumePCSAProcessa Pharmaceuticals3.7446 of 5 stars$0.90-1.1%$6.00+566.5%-89.3%$2.94MN/A0.0020News CoverageMYMDMyMD PharmaceuticalsN/A$1.23+7.0%N/A-87.3%$2.92MN/A0.009ALBTAvalon GloboCare0.8303 of 5 stars$2.65-4.7%N/A-66.0%$2.89M$1.26M0.005GNPXGenprex4.1641 of 5 stars$1.10flat$10.00+809.1%-89.4%$2.85MN/A0.0020News CoveragePositive NewsMTNBMatinas Biopharma0.7173 of 5 stars$0.540.0%N/AN/A$2.75M$1.10M0.0030Gap Up Related Companies and Tools Related Companies China SXT Pharmaceuticals Competitors Lipella Pharmaceuticals Competitors Psyence Biomedical Competitors InMed Pharmaceuticals Competitors Aravive Competitors Processa Pharmaceuticals Competitors MyMD Pharmaceuticals Competitors Avalon GloboCare Competitors Genprex Competitors Matinas Biopharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CYCC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYCC Stock Alerts